​

Corcept Therapeutics (CORT) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CORT Stock Forecast

Corcept Therapeutics (CORT) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $140.00, with a high of $145.00 and a low of $135.00. This represents a 96.68% increase from the last price of $71.18.

- $30 $60 $90 $120 $150 High: $145 Avg: $140 Low: $135 Last Closed Price: $71.18

CORT Stock Rating

Corcept Therapeutics stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 13 Buy (61.90%), 8 Hold (38.10%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 8 13 0 Strong Sell Sell Hold Buy Strong Buy

CORT Price Target Upside V Benchmarks

TypeNameUpside
StockCorcept Therapeutics96.68%
SectorHealthcare Stocks 24.81%
IndustryBiotech Stocks 65.78%

Price Target Trends

1M3M12M
# Anlaysts-27
Avg Price Target-$140.00$85.29
Last Closing Price$71.18$71.18$71.18
Upside/Downside-96.68%19.82%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2522---4
May, 2522---4
Apr, 2522---4
Mar, 2522---4
Feb, 2522---4
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 06, 2025Joon LeeTruist Financial$135.00$70.7490.84%89.66%
May 06, 2025Swayampakula RamakanthH.C. Wainwright$145.00$73.9496.10%103.71%
Oct 18, 2024Swayampakula RamakanthH.C. Wainwright$80.00$47.1769.60%12.39%
Sep 30, 2024Joon LeeTruist Financial$76.00$43.9373.00%6.77%
Aug 15, 2024Edward NashCanaccord Genuity$78.00$34.71124.72%9.58%
Jul 30, 2024David AmsellemPiper Sandler$38.00$36.125.20%-46.61%
Jul 30, 2024Swayampakula RamakanthH.C. Wainwright$45.00$36.5323.19%-36.78%
Jun 12, 2024Edward NashCanaccord Genuity$38.00$32.7915.89%-46.61%
Jun 10, 2024David AmsellemPiper Sandler$35.00$31.5111.08%-50.83%
Jun 04, 2024Joon LeeTruist Financial$65.00$31.59105.76%-8.68%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 06, 2025H.C. WainwrightBuyBuyhold
Oct 18, 2024Sandler O'NeillBuyBuyhold
Oct 18, 2024H.C. WainwrightBuyBuyhold
Sep 25, 2024Canaccord GenuityBuyBuyhold
Sep 18, 2024Sandler O'NeilUnderperformUnderperformhold
Sep 18, 2024Piper SandlerOverweightOverweighthold
Aug 15, 2024Canaccord GenuityBuyBuyhold
Jul 30, 2024Truist FinancialBuyBuyhold
Jul 30, 2024Piper SandlerOverweightOverweighthold
Jul 30, 2024H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$0 $1 $2 $3 $4 $5 $6 $7 $8 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.92$0.97$0.95$1.02$1.35----
Avg Forecast$0.84$0.89$0.96$0.92$1.36$1.91$3.20$4.85$6.86
High Forecast$0.88$0.94$1.01$0.94$1.45$2.66$3.67$6.54$7.21
Low Forecast$0.80$0.85$0.91$0.88$1.27$1.41$2.39$3.23$6.59
Surprise %9.52%8.99%-1.04%10.87%-0.74%----

Revenue Forecast

$0 $400M $800M $1B $2B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$353.87M$365.98M$401.86M$482.38M$675.04M----
Avg Forecast$358.48M$367.75M$403.88M$476.28M$691.84M$810.08M$1.04B$1.32B$1.66B
High Forecast$372.19M$381.81M$421.56M$495.04M$703.42M$836.21M$1.04B$1.32B$1.73B
Low Forecast$344.97M$353.89M$389.49M$461.63M$684.53M$792.21M$1.04B$1.32B$1.61B
Surprise %-1.28%-0.48%-0.50%1.28%-2.43%----

Net Income Forecast

$50M $210M $370M $530M $690M $850M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$106.01M$112.51M$101.42M$106.14M$139.73M----
Avg Forecast$103.37M$90.08M$107.54M$105.50M$151.97M$201.37M$395.01M$603.99M$766.55M
High Forecast$124.05M$108.10M$129.05M$126.60M$162.10M$297.40M$410.27M$730.61M$805.80M
Low Forecast$82.70M$72.07M$86.03M$84.40M$141.84M$157.99M$267.18M$360.84M$735.89M
Surprise %2.55%24.90%-5.69%0.61%-8.05%----

CORT Forecast FAQ

Is Corcept Therapeutics stock a buy?

Corcept Therapeutics stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 13 Buy, 8 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Corcept Therapeutics is a favorable investment for most analysts.

What is Corcept Therapeutics's price target?

Corcept Therapeutics's price target, set by 21 Wall Street analysts, averages $140 over the next 12 months. The price target range spans from $135 at the low end to $145 at the high end, suggesting a potential 96.68% change from the previous closing price of $71.18.

How does Corcept Therapeutics stock forecast compare to its benchmarks?

Corcept Therapeutics's stock forecast shows a 96.68% upside, outperforming the average forecast for the healthcare stocks sector (24.81%) and outperforming the biotech stocks industry (65.78%).

What is the breakdown of analyst ratings for Corcept Therapeutics over the past three months?

  • June 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 50.00% Strong Buy, 50.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Corcept Therapeutics’s EPS forecast?

Corcept Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $1.91, marking a 41.48% increase from the reported $1.35 in 2024. Estimates for the following years are $3.2 in 2026, $4.85 in 2027, and $6.86 in 2028.

What is Corcept Therapeutics’s revenue forecast?

Corcept Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $810.08M, reflecting a 20.00% increase from the reported $675.04M in 2024. The forecast for 2026 is $1.04B, followed by $1.32B for 2027, and $1.66B for 2028.

What is Corcept Therapeutics’s net income forecast?

Corcept Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $201.37M, representing an 44.11% increase from the reported $139.73M in 2024. Projections indicate $395.01M in 2026, $603.99M in 2027, and $766.55M in 2028.